Table 3 |
||
|
Reasons for non-adherence to the treatment advice of the treat-to-target strategy |
||
|
Remission (DAS28 < 2.6) (n = 553) |
Non-remission (DAS28 ≥ 2.6) (n = 539) |
|
|
|
||
|
Tapering off/discontinuing instead of continuing |
40 (7.2) |
|
|
Unknown |
12 |
|
|
Patient wish |
3 |
|
|
Side effects |
19 |
|
|
Clinical remission |
5 |
|
|
Other |
1 |
|
|
Continuing instead of tapering off/discontinuing |
34 (6.2) |
. |
|
Unknown |
23 |
|
|
Patient wish |
4 |
|
|
Active disease |
5 |
|
|
Other |
2 |
|
|
Intensifying instead of not intensifying* |
24 (4.3) |
. |
|
Unknown |
2 |
|
|
Patient wish |
2 |
|
|
Active disease |
20 |
|
|
Not intensifying* instead of intensifying |
. |
188 (34.9) |
|
Unknown |
29 |
|
|
Patient wish |
13 |
|
|
Side effects |
32 |
|
|
Clinical remission |
106 |
|
|
Other |
8 |
|
|
Other deviations from treatment advice |
10 (1.8) |
39 (7.2) |
|
Unknown |
5 |
10 |
|
Patient wish |
. |
2 |
|
Side effects |
4 |
16 |
|
Clinical remission |
. |
2 |
|
Other |
1 |
9 |
|
|
||
|
Data are presented of a total of 1097 visits of 100 patients with early rheumatoid arthritis, stratified by remission state according to the Disease Activity Score in 28 joints (DAS28). Values regarding the type of deviation are presented as number (%), values regarding the reasons for non-adherence are presented as number. *Including continuing, tapering off and discontinuing medication. |
||
|
Vermeer et al. Arthritis Research & Therapy 2012 14:R254 doi:10.1186/ar4099 |
||
